CASP8 Knockout A-549 Cell Line
Cat.No.:
EDC07644
Species:
Human
Cell Name:
A-549
Gene:
CASP8
Gene ID:
841
Size:
1×10⁶cells
CASP8 Knockout Cell Line (A549) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC07644 |
|---|---|
| Product Name | CASP8 Knockout A549 Cell Line |
| Cell Line | A-549 |
| Cellosaurus ID | CVCL_0023 |
| Cell Line Synonyms | A 549, A549, NCI-A549, A549/ATCC, A549 ATCC, A549ATCC, hA549 |
| Gene | CASP8 |
| NCBI Gene ID | |
| Gene Synonyms | ALPS2B|CAP4|Casp-8|FLICE|MACH|MCH5 |
| Summary |
This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes composed of a prodomain, a large protease subunit, and a small protease subunit. Activation of caspases requires proteolytic processing at conserved internal aspartic residues to generate a heterodimeric enzyme consisting of the large and small subunits. This protein is involved in the programmed cell death induced by Fas and various apoptotic stimuli. The N-terminal FADD-like death effector domain of this protein suggests that it may interact with Fas-interacting protein FADD. This protein was detected in the insoluble fraction of the affected brain region from Huntington disease patients but not in those from normal controls, which implicated the role in neurodegenerative diseases. Many alternatively spliced transcript variants encoding different isoforms have been described, although not all variants have had their full-length sequences determined. [provided by RefSeq, Jul 2008]
|
| Associated Diseases | Non-Small Cell Lung Carcinoma |
| Morphology | Adherent |
| Passage Ratio | 1/5-1/4 ,2days |
| Complete Culture Medium | F-12K + 10% FBS |
| Freezing Medium | 95% Complete culture medium + 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: A-549 | STR Info (Cell bank) Cell Line: A-549 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | Y | X | Y |
| CSF1PO | 10 | 12 | 10 | 12 |
| D2S1338 | 24 | 24 | ||
| D3S1358 | 16 | 16 | ||
| D5S818 | 11 | 11 | ||
| D7S820 | 8 | 11 | 8 | 11 |
| D8S1179 | 13 | 14 | 13 | 14 |
| D13S317 | 11 | 11 | ||
| D16S539 | 11 | 12 | 11 | 12 |
| D18S51 | 14 | 17 | 14 | 17 |
| D19S433 | 13 | 13 | ||
| D21S11 | 29 | 29 | ||
| FGA | 23 | 23 | ||
| Penta D | 9 | 9 | ||
| Penta E | 7 | 11 | 7 | 11 |
| TH01 | 8 | 9.3 | 8 | 9.3 |
| TPOX | 8 | 11 | 8 | 11 |
| vWA | 14 | 14 | ||
| D6S1043 | 11 | 13 | ||
| D12S391 | 18 | 18 | ||
| D2S441 | 10 | 13 | 10 | 13 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying CASP8 function, CASP8 Knockout A-549 Cell Line or CASP8 overexpression A-549 Cell Line?
The choice depends on whether you are studying CASP8 in lung cancer context for chemotherapy and TRAIL-targeted therapy research. The Knockout line is the standard tool for asking whether CASP8 is required for these processes in NSCLC context — CASP8 silencing/loss has been characterized in many cancers as an immune evasion and chemotherapy resistance mechanism; CASP8 status influences TRAIL-induced apoptosis. Overexpression is useful for studying CASP8 gain-of-function effects.
For lung cancer apoptosis research, the EDITGENE CASP8 Knockout in A-549 is highly relevant. This product complements the parallel CASP8 Knockouts in L-02 (normal hepatocyte) and A-375 (BRAF melanoma) for cross-background validation. Rescue with wild-type or catalytically-dead CASP8 enables structure-function studies. The knockout is valuable for studying death receptor-induced apoptosis in NSCLC, TRAIL-targeted therapy resistance, and apoptosis-necroptosis switching in lung cancer biology.
What are the application scenarios for this model?
Primary applications:
• NSCLC death receptor signaling: FAS/TRAIL-R-induced apoptosis analysis in NSCLC context.
• TRAIL-targeted therapy: in heterologous TRAIL-targeted therapy contexts, characterization of CASP8-dependent TRAIL-induced apoptosis.
• Cross-background validation: parallel analysis with CASP8 KOs in L-02 and A-375 (both available) for cross-tissue context studies.
• Lung cancer chemotherapy: cisplatin, paclitaxel-induced apoptosis analysis in CASP8-null cells.
EDITGENE recommends this NSCLC model for researchers investigating death receptor apoptosis and TRAIL-targeted therapy resistance in lung cancer.
Is this CASP8 Knockout A-549 Cell Line compatible with overexpression rescue experiments?
Yes. CASP8 rescue experiments in A-549 are well-suited for lung cancer apoptosis research:
• Construct design: same considerations as CASP8/L-02 rescue — preserve DED and protease domains.
• Catalytically-dead C360S rescue: enables separation of proteolytic from scaffolding functions in NSCLC context.
• Lung cancer mutation rescue: cancer-associated CASP8 mutations enable studies of CASP8 silencing in tumor biology.
• Functional readout: rescue should restore TRAIL- and FAS-induced apoptosis in NSCLC context.
A-549 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
download